Page 80 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

56 David S. Younger

[116] Tomic-Lucic, A., Petrovic, R., Radak-Perovic, M., et al. Late-onset systemic lupus
erythematosus: clinical features, course, and prognosis. Clin. Rheumatol. 2013;
32:1053-1058.

[117] Johnson, R. T., Richardswon, E. P. The neurological manifestations of systemic lupus
erythematosus. Medicine 1968; 47:337-369.

[118] Estes, D., Christian, C. L. The natural history of systemic lupus erythematosus by
prospective analysis. Medicine 1971; 50:85-95.

[119] Devinsky, O., Petito, C. K., Alonso, D. R. Clinical and Neuropathological findings in
systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic
thrombocytopenic purpura. Ann. Neurol. 1988; 23:380-384.

[120] Feinglass, E. J., Arnett, F. C., Dorsch, C. A., et al. Neuropsychiatric manifestations of
systemic lupus erythematosus: Diagnosis, clinical spectrum, and relationship to other
features of the disease. Medicine 1976; 55:323-339.

[121] Mintz, G., Fraga, A. Arteritis in systemic lupus erythematosus. Arch. Intern. Med.
1965; 116:55-66.

[122] Trevor, R. P., Sondheimer, F. K., Fessel, W. J., et al. Angiographic demonstration of
major cerebral vessel occlusion in systemic lupus erythematosus. Neuroradiology 1972;
4:202-207.

[123] Younger, D. S., Sacco, R., Levine, S. R., et al. Major cerebral vessel occlusion in SLE
due to circulating anticardiolipin antibodies. Stroke 1994; 25:912-914.

[124] Levine, S. R., Welch, K. M. A. The spectrum of neurologic disease associated with
antiphospholipid antibodies. Arch. Neurol. 1987; 44:876-883.

[125] McCaffrey, L. M., Petelin, A., Cunha, B. A. Systemic lupus erythematosus (SLE)
cerebritis versus Listeria monocytogenes meningoencephalitis in a patient with
systemic lupus erythematosus on chronic corticosteroid therapy: The diagnostic
importance of cerebrospinal fluid (CSF) of lactic acid levels. Heart and Lung 2012; 41:
394-397.

[126] Aletaha, D., Neogi, T., Silman, A. J., et al. 2010 Rheumatoid arthritis classification
criteria. An American College of Rheumatology/European League Against Rheumatism
Collaborative Initiative. Arthritis Rheum. 2010; 62:2569-2581.

[127] Turesson, C. Extra-articular rheumatoid arthritis. Curr. Opin. Rheumatol. 2013; 25:360-
366.

[128] Turesson, C., Jacobsson, L. T. Epidemiology of extra-articular manifestations in
rheumatoid arthritis. Scand. J. Rheumatol. 2004; 33:65-72.

[129] Scott, D. G., Bacon, P. A. Intravenous cyclophosphamide plus methylprednisolone in
treatment of systemic rheumatoid vasculitis. Am. J. Med. 1984; 76:377-384.

[130] Watts, R. A., Mooney, J., Lane, S. E., et al. Rheumatoid vasculitis: becoming extinct?
Rheumatology 2004; 2012; 43:920-923.

[131] Myasoedova, E., Crowson, C. S., Turesson, C., et al. Incidence of extra-articular
rheumatoid arthritis in Olmsted County Minnesota, in 1995-2007 versus 1985-1994: a
population-based study. J. Rheumatology 2011; 38:983-989.

[132] Vollerstein, R. S., Conn, D. L., Ballard, D. J., et al. Rheumatoid vasculitis: survival and
risk factors. Medicine 1986; 65:365-375.

[133] Rasker, J. J., Cosh, J. A. Cause and age at death in a prospective study of 100 patients
with rheumatoid arthritis. Ann. Rheum. Dis. 2982; 40:115-120.

Complimentary Contributor Copy